Biotechnology Companies By Pb Ratio

Price To Book
Price To BookEfficiencyMarket RiskExp Return
1PTCT PTC Therapeutics
1.74 K
 0.12 
 3.64 
 0.45 
2ALNY Alnylam Pharmaceuticals
1.01 K
(0.01)
 2.21 
(0.03)
3RNAC Cartesian Therapeutics
630.3
 0.09 
 6.49 
 0.60 
4RYTM Rhythm Pharmaceuticals
328.36
 0.15 
 3.22 
 0.49 
5PLUR Pluri Inc
306.56
 0.02 
 5.06 
 0.09 
6FBLG FibroBiologics, Common Stock
300.03
 0.12 
 10.13 
 1.18 
7MRSN Mersana Therapeutics
255.54
 0.11 
 6.73 
 0.74 
8AGEN Agenus Inc
218.61
(0.09)
 5.17 
(0.48)
9GALT Galectin Therapeutics
207.7
 0.04 
 3.11 
 0.12 
10APLT Applied Therapeutics
201.63
 0.09 
 9.63 
 0.83 
11INDV Indivior PLC Ordinary
145.25
(0.02)
 4.23 
(0.07)
12EVAX Evaxion Biotech AS
127.63
(0.15)
 5.75 
(0.88)
13BBIO BridgeBio Pharma
123.68
 0.01 
 3.69 
 0.04 
14CARM Carisma Therapeutics
114.1
(0.12)
 2.88 
(0.34)
15HURA TuHURA Biosciences
104.22
 0.01 
 10.03 
 0.05 
16OCEA Ocean Biomedical
100.67
(0.14)
 4.44 
(0.64)
17ESPR Esperion Therapeutics
98.42
 0.14 
 4.61 
 0.62 
18PROK ProKidney Corp
91.32
(0.04)
 6.16 
(0.22)
19TVTX Travere Therapeutics
76.1
 0.26 
 4.60 
 1.18 
20CHRS Coherus BioSciences
73.19
 0.01 
 6.67 
 0.05 
The analysis above is based on a 90-day investment horizon and a default level of risk. Use the Portfolio Analyzer to fine-tune all your assumptions. Check your current assumptions here.
Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities. Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.